Rallybio Corporation
RLYB · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | – | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 0% | 0% | 457.9% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 100% | 100% | 100% | 21.1% |
| EBITDA | $0 | -$0 | -$0 | -$0 |
| % Margin | 7,571.2% | -4,731.6% | -4,548.1% | -30,468.4% |
| Net Income | $0 | -$0 | -$0 | -$0 |
| % Margin | 7,554.7% | -4,576.9% | -4,452.4% | -29,063.2% |
| EPS Diluted | 0.36 | -0.22 | -0.21 | -0.25 |
| % Growth | 263.6% | -4.8% | 16% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |